参考文献
［1］Ferlay J，Soerjomataram I，Ervik M，et al.GLOBOCAN 2012 v1.0，Cancer Incidence and Mortality Worldwide：IARC Cancer Base No.11 ［Internet］.Lyon，France：IARC，2014.
［2］Chen WQ，Zheng RS，Zeng HM，et al.Annual report on status of cancer in China，2011.Chin J Cancer Res，2015，27（1）：2-12.
［3］Chen WQ，Zheng RS，Baade PD，et al.Cancer Statistics in China，2015.CA Cancer J Clin，2016，66：115-132.
［4］赫捷，陈万青.2012中国肿瘤登记年报.北京：军事医学科学出版社，2012.
［5］Li J，Zhang BN，Fan JH，et al.A Nation-Wide multicenter 10-year（1999-2008）retrospective clinical epidemiological study of female breast cancer in China.BMC cancer，2011，11：364-375.
［6］Wang Q，Li J，Zheng S，et al.Breast cancer stage at diagnosis and area-based socioeconomic status：a multicenter 10-year retrospective clinical epidemiological study in China.BMC cancer，2012，12：122-130.
［7］Perou CM，Srlie T，Eisen MB，et al.Molecular portraits of human breast tumors.Nature，2000，406（6797）：747-752.
［8］Su Y，Zheng Y，Zheng W，et al.Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women：a population-based cohort study.BMC Cancer，2011，11：292.
［9］Wiechmann L，Sampson M，Stempel M，et al.Presenting Features of Breast Cancer Differ by Molecular Subtype.Ann Surg Oncol，2009，16（10）：2705-2710.
［10］Zhao J，Liu H，Wang M，et al.Characteristics and prognosis for molecular breast cancer subtypes in Chinese women.J Surg Oncol，2009，100（2）：89-94.
［11］Collaborative Group on Hormonal Factors in Breast Cancer.Familial breast cancer：collaborative reanalysis of individual data from 52 epidemiological studies including 58，209 women with breast cancer and 101，986 women without the disease.Lancet，2001，358（9291）：1389-1399.
［12］Tamimi RM，Colditz GA，Hazra A，et al.Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer.Breast Cancer Res Treat，2012，131（1）：159-167.
［13］Setiawan VW，Monroe KR，Wilkens LR，et al.Breast cancer risk factors defined by estrogen and progesterone receptor status：the multiethnic cohort study.Am J Epidemiol，2009，169（10）：1251-1259.
［14］Yang XR，Sherman M E，Rimm DL，et al.Differences in risk factors for breast cancer molecular subtypes in a population-based study.Cancer Epidemiol Biomarkers Prev，2007，16（3）：439-443.
［15］Schwartz GF，Hughes KS，Lynch HT，et al.Proceedings of the international consensus conference on breast cancer risk，genetics，& risk management.April，2007.Breast J，2009，15（1）：4-16.
［16］Turnbull C，Rahman N.Genetic predisposition to breast cancer：past，present，and future.Annu Rev Genomics Hum Genet，2008，9：321-345.
［17］Antoniou A，Pharoah PD，Narod S，et al.Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history：a combined analysis of 22 studies.Am J Hum Genet，2003，72（5）：1117-1130.
［18］Chen S，Parmigiani G.Meta-analysis of BRCA1 and BRCA2 penetrance.J Clin Oncol，2007，25：1329-1333.
［19］Mavaddat N，Peock S，Frost D，et al.Cancer risks for BRCA1 and BRCA2 mutation carriers：results from prospective analysis of EMBRACE.J Natl Cancer Inst，2013，105（11）：812-822.
［20］Gabai-Kapara E，Lahad A，Kaufman B，et al.Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.Proc Natl Acad，2014，111（39）：14205-14210.
［21］American Cancer Society.Special Section：Multiple Primary Cancers.Cancer Facts and Figures 2009.Atlanta，GA：American Cancer Society，2009.
［22］Santen RJ.Benign Breast Disease in Women//De Groot LJ，Beck-Peccoz P，Chrousos G，et al，editors.Endnotext.South Dartmouth，MA：MDText.com，Inc，2014.
［23］Bertrand KA，Scott CG，Tamimi RM，et al.Dense and nondense mammographic area and risk of breast cancer by age and tumor characteristics.Cancer Epidemiol Biomarkers Prev，2015，24（5）：798-809.
［24］Key T，Appleby P，Barnes I，et al.Endogenous sex hormones and breast cancer in postmenopausal women：reanalysis of nine prospective studies.J Natl Cancer Inst，2002，94（8）：606-616.
［25］陶苹，胡耀月黄源，等.亚裔女性乳腺癌危险因素的Meta分析.中华流行病学杂志，2011，32（2）：164-169.
［26］Collaborative Group on Hormonal Factors in Breast Cancer.Menarche，menopause，and breast cancer risk：individual participant meta-analysis，including 118 964 women with breast cancer from 117 epidemiological studies.Lancet Oncol，2012，13（11）：1141-1151.
［27］Ritte R，Tikk K，Lukanova A，et al.Reproductive factors and risk of hormone receptor positive and negative breast cancer：a cohort study.BMC Cancer，2013，13：584-592.
［28］Phipps AI，Malone KE，Porter PL，et al.Reproductive and hormonal risk factors for postmenopausal luminal，HER2-overexpressing，and triple-negative breast cancer.Cancer，2008，113（7）：1521-1526.
［29］Albrektsen G，Heuch I，Hansen S，et al.Breast cancer risk by age at birth，time since birth and time intervals between births：exploring interaction effects.British J Cancer，2005，92：167-175.
［30］Collaborative Group on Hormonal Factors in Breast Cancer.Breast cancer and breastfeeding：collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries，including 50 302 women with breast cancer and 96 973 women without the disease.Lancet，2002，360（9328）：187-195.
［31］Anderson KN，Schwab RB，Martinez ME.Reproductive risk factors and breast cancer subtypes：a review of the literature.Breast Cancer Res Treat，2014，144（1）：1-10.
［32］Islami F，Liu Y，Jemal A，et al.Breastfeeding and breast cancer risk by receptor status—a systematic review and meta-analysis.Ann Oncol，2015，26（12）：2398-2407.
［33］Chlebowski RT，Manson JE，Anderson GL，et al.Estrogen plus progestin and breast cancer incidence and mortality in the Women’s Health Initiative Observational Study.J Natl Cancer Inst，2013，105：526-535.
［34］Manson JE，Chlebowski RT，Stefanick ML，et al.Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials.JAMA，2013，310（13）：1353-1368.
［35］Collaborative Group on Hormonal Factors in Breast Cancer.Breast cancer and hormonal contraceptives：collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies.Lancet，1996，347（9017）：1713-1727.
［36］Dolle JM，Daling JR，White E，et al.Risk Factors for Triple-negative Breast Cancer in Women Under the Age of 45 Years.Cancer Epidemiol Biomarkers Prev，2009，18（4）：1157-1166.
［37］Bjerkaas E，Parajuli R，Weiderpass E，et al.Smoking duration before first childbirth：an emerging risk factor for breast cancer? Results from 302，865 Norwegian women.Cancer Causes Control，2013，24（7）：1347-1356.
［38］Catsburg C，Miller AB，Rohan TE.Active cigarette smoking and risk of breast cancer.Int J Cancer，2015，136（9）：2204-2209.
［39］Gaudet MM，Gapstur SM，Sun J，et al.Active smoking and breast cancer risk：original cohort data and meta analysis.J Natl Cancer Inst，2013，105（8）：515-525.
［40］Yang Y，Zhang F，Skrip L，et al.Lack of an association between passive smoking and incidence of female breast cancer in nonsmokers：evidence from 10 prospective cohort studies.PLoS One，2013，8（10）：e77029.
［41］Pirie K，Beral V，Peto R，et al.Passive smoking and breast cancer in never smokers：prospective study and meta analysis.Int J Epidemiol，2008，37（5）：1069-1079.
［42］Luo J，Margolis KL，Wactawski-Wende J，et al.Association of active and passive smoking with risk of breast cancer among postmenopausal women：a prospective cohort study.BMJ，2011，342：d1016.
［43］Hamajima N，Hirose K，et al.Alcohol，tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies，including 58，515 women with breast cancer and 95，067 women without the disease.Br J Cancer，2002，87（11）：1234-1245.
［44］Chen WY，Rosner B，Hankinson SE，et al.Moderate alcohol consumption during adult life，drinking patterns，and breast cancer risk.JAMA，2011，306（17）：1884-1890.
［45］Liu Y，Nguyen N，Colditz GA.Links between alcohol consumption and breast cancer：a look at the evidence.Women’s Health（London，England），2015，11（1）：65-77.
［46］Suzuki R，Orsini N，Mignone L，et al.Alcohol intake and risk of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis of epidemiological studies.Int J Cancer，2008，122（8）：1832-1841.
［47］Li CI，Chlebowski RT，Freiberg M，et al.Alcohol consumption and risk of postmenopausal breast cancer by subtype：the women’s health initiative observational study.J Natl Cancer Inst，2010，102（18）：422-1431.
［48］Alexander DD，Morimoto LM，Mink PJ，et al.Summary and meta-analysis of prospective studies of animal fat intake and breast cancer.Nutr Res Rev，2010，23（1）：169-179.
［49］Linos E，Willett WC，Cho E，et al.Adolescent diet in relation to breast cancer risk among premenopausal women.Cancer Epidemiol Biomarkers Prev，2010，19（3）：689-696.
［50］Fritz H，Seely D，Flower G，et al.Soy，red clover，and isoflavones and breast cancer：a systematic review.PLoS One，2013，8（11）：e81968.
［51］Jung S，Spiegelman D，Baglietto L，et al.Fruit and vegetable intake and risk of breast cancer by hormone receptor status.J Natl Cancer Inst，2013，105（3）：219-236.
［52］La Vecchia C，Giordano SH，Hortobagyi GN，et al.Overweight，obesity，diabetes，and risk of breast cancer：interlocking pieces of the puzzle.Oncologist，2011，16（6）：726-729.
［53］Nelson HD，Zakher B，Cantor A，et al.Risk factors for breast cancer for women aged 40 to 49 years：a systematic review and meta-analysis.Ann Intern Med，2012，156（9）：635-648.
［54］Ritte R，Lukanova A，Berrino F，et al.Adiposity，hormone replacement therapy use and breast cancer risk by age and hormone receptor status：a large prospective cohort study.Breast Cancer Res，2012，14（3）：R76.
［55］Huang WY，Newman B，Millikan RC，et al.Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status.Am J Epidemiol，2000，151（7）：703-714.
［56］Yang XR，Chang-Claude J，Goode EL，et al.Associations of breast cancer risk factors with tumor subtypes：a pooled analysis from the Breast Cancer Association Consortium studies.J Natl Cancer Inst，2011，103（3）：250-263.
［57］Millikan RC，Newman B，Tse CK，et al.Epidemiology of basal-like breast cancer.Breast Cancer Res Treat，2008，109（1）：123-139.
［58］Hildebrand JS，Gapstur SM，Campbell PT，et al.Recreational physical activity and leisure time sitting in relation to postmenopausal breast cancer risk.Cancer Epidemiol Biomarkers Prev，2013，22（10）：1906-1912.
［59］Wu Y，Zhang D，Kang S.Physical activity and risk of breast cancer：a meta-analysis of prospective studies.Breast Cancer Res Treat，2013，137（3）：869-882.
［60］Preston DL，Mattsson A，Holmberg E，et al.Radiation effects on breast cancer risk：a pooled analysis of eight cohorts.Radiat Res，2002，158（2）：220-235.
［61］Travis LB，Hill DA，Dores GM，et al.Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease.JAMA，2003，290（4）：465-475.
［62］Clapp RW，Jacobs MM，Loechler EL.Environmental and occupational causes of cancer：new evidence 2005-2007.Rev Environ Health，2008，23（1）：1-37.
［63］Bonner MR，Han D，Nie J，et al.Breast cancer risk and exposure in early life to polycyclic aromatic hydrocarbons using total suspended particulates as a proxy measure.Cancer Epidemiol Biomarkers Prev，2005，14（1）：53-60.
［64］孔维佳，蒋建东.以EGFR家族受体酪氨酸激酶为靶点的抗肿瘤治疗研究进展.中国药理学通报，2003，19（8）：847-851.
［65］吴健虹，谢秋玲，陈小佳，等.表皮生长因子受体EGFR及其信号转导.生命科学，2006，18（2）：116-122.
［66］蒙燕，陈樟树.人表皮生长因子受体家族及其抑制剂在临床肿瘤治疗中的应用.福建医药杂志，2015，37（1）：119-121.
［67］代梅，郭建辉.靶向EGFR家族的抗肿瘤药物研究进展.生命科学，2009，21（3）：412-417.
［68］徐兵河.乳腺癌靶向治疗原则和实践.北京：人民卫生出版社，2015.
［69］Hynes NE，Lane HA.ERBB receptors and cancer：the complexity of targeted inhibitors.Nat Rev Cancer，2005，5（5）：341-354.
［70］Dawson JP，Berger MB，Lin CC，et al.Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface.Mol Cell Biol，2005，25（17）：7734-7742.
［71］Naidu R，Yadav M，Nair S，et al.Expression of c-erbB3 protein in primary breast carcinomas.Br J Cancer，1998，78（10）：1385-1390.
［72］Osaki A，Toi M，Yamada H，et al.Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients.Am J Surg，1992，164（4）：323-326.
［73］Linderholm B，Andersson J，Lindh B，et al.Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor（VEGF）and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment.Eur J Cancer，2004，40（1）：33-42.
［74］Konecny GE，Meng YG，Untch M，et al.Association between HER2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients.Clin Cancer Res，2004，10（5）：1706-1716.
［75］Carey LA，Rugo HS，Marcom PK，et al.TBCRC 001：randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.J Clin Oncol，2012，30（21）：2615-2623.
［76］Baselga J，Gómez P，Greil R，et al.Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.J Clin Oncol，2013，31（20）：2586-2592.
［77］Di Leo A，Gomez HL，Aziz Z，et al.Phase III，double-blind，randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.J Clin Oncol，2008，26（34）：5544-5552.
［78］Johnston S，Pippen J Jr，Pivot X，et al.Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.J Clin Oncol，2009，27：5538-5546.
［79］Lee Y，Cho S，Seo JH，et al.Correlated expression of erbB-3 with hormone receptor expression and favorable clinical outcome in invasive ductal carcinomas of the breast.Am J Clin Pathol，2007，128（6）：1041-1049.
［80］Chuu CP，Chen RY，Barkinge JL，et al.Systems-level analysis of ErbB4 signaling in breast cancer：a laboratory to clinical perspective.Mol Cancer Res，2008，6（6）：885-891.
［81］Martin M，Bonneterre J，Geyer CE，et al.A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.Eur J Cancer，2013，49（18）：3763-3772.
［82］魏兵，步宏.HER2与乳腺癌：生物学特点、临床意义及检测.华西医学，2004，19（2）：319-320.
［83］孙红，王浩.HER2与乳腺癌研究进展.现代肿瘤医学，2006，14（3）：365-367.
［84］张建会.HER2与乳腺癌关系的研究.中国医学检验杂志，2009，10：379-382.
［85］姜扩，王立锋，裘秀春.HER2与乳腺癌靶向治疗的研究进展.实用癌症杂志，2010，25（4）：425-432.
［86］Ullrich A，Coussens L，Hayflick JS，et al.Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells.Nature，1984，309（5967）：418-425.
［87］Schecher AL，Stern DF，Vaidyanathan L，et al.The neu oncogene：An erb-B-related gene encoding a 185000-M，tumour antigen.Nature，1984，312（5994）：513-516.
［88］Slamon DJ，Clark GM，Wong SG，et al.Human breast cancer，correlation of relapse and with amplification of the HER2/neu oncogene.Science，1987，235（4785）：177-181.
［89］Brennan PJ，Kaumagai T，Berezov A，et al.HER2/neu mechanisms of dimerization/ Ligomerization.Oncogene，2000，19（53）：6093-6101.
［90］Ross JS，Fletcher JA.The HER2/neu Oncogene in Breast Cancer：Prognostic Factor，Predictive Factor，and Target for Therapy.Oncologist，1998，3（4）：237-252.
［91］Ross JS，Fletcher JA.The HER2/neu oncogene in breast cancer：prognostic factor，predictive factor and target for therapy.Stem Cells，1998，16（6）：413-428.
［92］Allred DC，Clark GM，Molina R，et al.Over expression of HER2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.Hum Pathol，1992，23（9）：974-979.
［93］Gonzalez-Angulo AM，Litton JK，Broglio KR，et al.High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive，node-negative tumors 1 cm or smaller.J Clin Oncol，2009，27（34）：5700-5706.
［94］Marty M，Cognetti F，Maraninchi D，et al.Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment：the M77001 study group.J Clin Oncol，2005，23（19）：4265-4274.
［95］Shou J，Massarweh S，Osborne CK，et al.Mechanisms of tamoxifen resistance：increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.J Natl Cancer Inst，2004，96（12）：926-935.
［96］Cho HS，Mason K，Ramyar KX，et al.Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.Nature，2003，421（6924）：756–760.
［97］Agus DB，Akita RW，Fox WD，et al.Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.Cancer Cell，2002，2（2）：127–137.
［98］Diermeier S，Horvath G，Knuechel-Clarke R，et al.Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.Exp CellRes，2005，304（2）：604–619.
［99］Egeblad M，Mortensen OH，Jaattela M.Truncated ErbB2 receptor enhances ErbB1 signaling andinduces reversible，ERK-independent loss of epithelial morphology.Int J Cancer，2001，94（2）：185–191.
［100］Liu PC，Liu X，Li Y，et al.Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells.Cancer.Biol Ther，2006，5（6）：657–664.
［101］Molina MA，Codony-Servat J，Albanell J，et al.Trastuzumab（herceptin），a humanized anti-Her2 receptor monoclonal antibody，inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.Cancer Res，2001，61（12）：4744–4749.
［102］Yakes FM，Chinratanalab W，Ritter CA，et al.Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27，cyclin D1，and antitumor action.Cancer Res，2002，62（14）：4132-4141.
［103］Ram TG，Schelling ME，Hosick HL，et al.Blocking HER2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER2 gene amplification.Cell Growth Differ，2000，11（3）：173-183.
［104］Lee-Hoeflich ST，Crocker L，Yao E，et al.A central role for HER3 in HER2-amplified breast cancer：implications for targeted therapy.Cancer Res，2008，68（14）：5878-5887.
［105］Junttila TT，Akita RW，Parsons K，et al.Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.Cancer Cell，2009，15（5）：429-440.
［106］Nagata Y，Lan KH，Zhou X，et al.PTEN activation contributes to tumor inhibition by trastuzumab，and loss of PTEN predicts trastuzumab resistance in patients.Cancer Cell，2004，6（2）：117–127.
［107］Fujita T，Doihara H，Kawasaki K，et al.PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer.Br J Cancer，2006，94（2）：247-252.
［108］Yang W，Klos K，Yang Y，et al.ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A，C，and D in human breast carcinoma.Cancer，2002，94（11）：2855-2861.
［109］Izumi Y，Xu L，di TE，et al.Tumour biology：herceptin acts as an anti-angiogenic cocktail.Nature，2002，416（6878）：279–280.
［110］Clynes RA，Towers TL，Presta LG，et al.Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets.Nature Medicine，2000，6（4）：443–446.
［111］Arnould L，Gelly M，Penault-Llorca F，et al.Trastuzumab-based treatment of HER2-positive breast cancer：an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer，2006，94（2）：259–267.
［112］Gennari R，Menard S，Fagnoni F，et al.Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2.Clin Cancer Res，2004，10（17）：5650-5655.
［113］Franklin MC，Carey KD，Vajdos FF，et al.Insights into ErbB signaling.Cancer Cell，2004，5（4）：317–328.
［114］Agus DB，Akita RW，Fox WD，et al.Targeting ligand-activated ErbB2 signaling inhibits breast and tumor growth.Cancer Cell，2002，（2）：127–137.
［115］Brockhoff G，Heckel B，Schmidt-Bruecken E，et al.Differential impact of Cetuximab，Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation.Cell Prolif，2007，40（4）：488–507.
［116］Lewis Phillips GD，Li G，Dugger DL，et al.Targeting HER2-positive breast cancer with trastuzumab-DM1，an antibody cytotoxic drug conjugate.Cancer Res，2008，68（22）：9280-9290.
［117］Junttila TT，Li G，Parsons K，et al.Trastuzumab-DM1（T-DM1）retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.Breast Cancer Res Treat，2011，128（2）：347-356.
［118］Moasser MM，Basso A，Averbuch SD，et al.The tyrosine kinase inhibitor ZD1839（“Iressa”）inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.Cancer Research，2001，61（19）：184–7188.
［119］Wood ER，Truesdale AT，McDonald OB，et al.A unique structure for epidermal growth factor receptor bound to GW572016（Lapatinib）：relationships among protein conformation，inhibitor off-rate，and receptor activity intumor cells.Cancer Res，2004，64（18）：6652–6659.
［120］Xia W，Mullin RJ，Keith BR，et al.Anti-tumor activity of GW572016：a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.Oncogene，2002，21（41）：6255–6263.
［121］O’Brien NA，Browne BC，Chow L，et al.Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab butnot lapatinib.Mol Cancer Ther，2010，9（6）：1489-1502.
［122］Xia W，Liu LH，Ho P，et al.Truncated ErbB2 receptor（p95ErbB2）is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2kinase inhibitor GW572016.Oncogene，2004，23（3）：646-653.